Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. - Wikidata - wikimedia - TriplyDB

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

http://www.wikidata.org/entity/Q35664106

about

Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Activation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes Virus Cell Cycle Regulatory Functions of the KSHV Oncoprotein LANA Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation.Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest MDM2, MDMX and p53 in oncogenesis and cancer therapy A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation Survivin is a therapeutic target in Merkel cell carcinoma.Contribution of viral mimics of cellular genes to KSHV infection and disease.Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1 mediated signaling Phosphorylation of the chromatin binding domain of KSHV LANA Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Ribosomal protein S6 interacts with the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.Mdm2 promotes systemic lupus erythematosus and lupus nephritis Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions.Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.Regulation of the Abundance of Kaposi's Sarcoma-Associated Herpesvirus ORF50 Protein by Oncoprotein MDM2 Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor Murine Gammaherpesvirus 68 LANA and SOX Homologs Counteract ATM-Driven p53 Activity during Lytic Viral Replication mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders Role of Kaposi's sarcoma-associated herpesvirus C-terminal LANA chromosome binding in episome persistence.Targeting the MDM2-p53 interaction for cancer therapy The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis

P2860

Q21135231-F1C81110-5D36-40A9-A9BB-B21B60EAE987 Q24651380-5A8ECE27-C456-4FF9-B4A1-61AF55BDD858 Q26743368-BB9EAFC0-9C31-4FED-B9E8-36787D614E73 Q26749612-AF8FA041-C261-48D3-8158-F809B15D4650 Q27020978-1104E89D-46C8-4869-8146-363D6F7B2574 Q27318801-E5715B27-BAD5-4E93-8688-67EC3FD7DF3D Q28485399-2E25FA6A-291F-4A89-AD4F-6E87F818F795 Q30482603-7001A165-D756-453B-B42B-12E1205341E4 Q33301012-85015ABC-672C-4EB6-A3F1-DA5AE2689289 Q33545232-9B79EE7D-EC39-4CC0-9DCE-6DAEAF7FF7EB Q33826818-2FE04ACC-D750-4436-8992-B9884AAFCCFB Q34166049-3EE41880-E2B8-48B4-A064-EF229E91D39D Q34179693-E9FC39F3-7168-4EAF-ACCB-8AC5C60D8B7A Q34186981-940B3242-7185-4178-AD08-E5A8EEF9F202 Q34273814-AEDDADDF-33EF-4C9B-9409-7111266AA20B Q34303583-186111DF-CD47-4D8B-A231-A97C9228076D Q34443056-63D32CEB-B173-45A7-9AF1-59C19A176224 Q34456086-0C96CBFD-7644-4327-BDF5-741F766585A5 Q34541350-9060BDF4-70D5-4CE2-8435-B331A5ECDEDB Q34982229-5750B059-0ACF-40FA-B892-C680ACAC9D5E Q35192690-01EFE425-9B2C-4486-AAC9-B71DDA07AE39 Q35235757-F078B306-AB7E-4C23-A317-08EE4731FB78 Q35758450-B1658265-485D-450D-AEFC-90D14D746D51 Q35927487-E8624738-2231-4AC9-9634-3A55A117274A Q35954902-95EDC526-656D-40C8-9B40-5E1AA6D5E8AD Q35973676-C7DBF2AF-B2E1-4A25-AFB1-7C751C9F69BD Q36023151-F35079C4-7EF1-4A5C-B962-BD52BC66C716 Q36048192-CBCE3ADD-F274-4B10-96AA-A2C8B6645994 Q36106299-46E6F51D-A05B-47F9-899B-F0CB42739558 Q36152200-E3A28551-9F5F-4582-AA2A-8F0C87A231F3 Q36423989-FBD16120-B135-4EB3-9643-11799F61FD2B Q36736774-3CDBEF39-0CA6-433F-8105-2DA632104B4E Q36745445-3050E1E5-542D-4E38-A184-5EE1CA305EAD Q36890993-A7249CD0-57C5-4EE6-BA13-D1A70FF1242D Q37016504-5F958E85-CFA7-434F-90FB-36551A26DD48 Q37157253-AF03131B-FCBF-4775-BBF5-861697C835BC Q37177586-8FE5541B-AFBC-4F4D-87A7-1F8B1A5E9639 Q37380228-BA53363A-6E2F-4816-8DE7-65D5F0815870 Q37477829-5C43DE20-633F-46B5-8526-BBABF67918B0 Q37593234-CF78DD6F-9270-4D4F-937E-FCFB065344AF

P2860

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

http://www.wikidata.org/entity/Q35664106

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

@ast

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

@en

type

label

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

@ast

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

@en

prefLabel

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

@ast

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

@en

P1433

Q35664106-2627D865-19E9-4752-9BFA-1A9A36D37157

P1476

Q35664106-005D971B-3A7F-480A-86AF-3FC30C2BA3A2

P2093

Q35664106-2DC43BE9-5C13-4708-B1D9-BD81A379B3F6

Q35664106-5E042889-F49B-4DCD-98C8-7EA1E65C4476

Q35664106-9DC7D027-A87A-433B-BBA8-842835A5E913

Q35664106-C0FB21FF-0877-4F5D-833A-25AD016997F9

Q35664106-C3C282A8-123D-43A7-8AC5-8D2593EDB1C2

Q35664106-EB1169C6-1079-4022-A3B3-A2477A4FE7AF

P2860

Q35664106-0E57284F-9A37-48DA-81A9-B1AF9CD4652B

Q35664106-10E8AD88-68F7-40B1-9004-03438ED6943B

Q35664106-1999CD8C-F97C-42AE-A532-A4ED1F69B0E9

Q35664106-1B55FF5A-2382-4C0E-AB5F-ED2E2E5B4D04

Q35664106-1C6BDE97-BAFF-4B76-96EA-1B88BC88E125

Q35664106-1D9D1AF6-7F88-4495-8DE0-9F3CB0A5CBBC

Q35664106-1F28D370-9562-4E32-AA9E-249F4CD9592D

Q35664106-20F076AF-415A-4C43-9AC0-7CEC6376BC88

Q35664106-23710B66-9D44-43A5-9AD3-BF64C1179473

Q35664106-273EE8EA-E06F-4C93-86FD-4DC79CC3CB8A

P304

Q35664106-9B848ED6-8A8D-4009-AC08-17CF0B9A0362

P31

Q35664106-7AE585DD-3D9F-47FE-B985-305CC94C6BE4

P356

Q35664106-C43C67D2-04EA-44D5-AC72-C9CCC0AE3B5A

P407

Q35664106-BB61E6A6-09E8-4399-B9A8-E94391AA2877

P433

Q35664106-921B3BA9-B7AC-4685-970A-766AB289E3F3

P478

Q35664106-656833CE-84D4-4E27-B2E8-821D92E86586

P50

Q35664106-A807C251-6B9F-42A1-8B68-AB5F88E23DA8

Q35664106-AF2C6C9C-C1A2-4DDD-A563-1E07F19E9C4E

P577

Q35664106-B3BC0EFA-83D3-43BD-9431-3CAA95EE4FB0

P5875

Q35664106-E8549CC9-1C9D-48D3-B2C0-152E8FBC4353

P698

Q35664106-673BA4D0-A663-4DA2-BAA4-47548B7D6222

P932

Q35664106-93747C34-6822-4512-A842-A3B39B761E4E

P356

P1433

Journal of Clinical Investigation

P1476

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas

@en

P2093

Grzegorz Sarek

http://www.w3.org/2001/XMLSchema#string

Guergana Iotzova

http://www.w3.org/2001/XMLSchema#string

Juergen Haas

http://www.w3.org/2001/XMLSchema#string

Juulia Enbäck

http://www.w3.org/2001/XMLSchema#string

Marikki Laiho

http://www.w3.org/2001/XMLSchema#string

Sari Kurki

http://www.w3.org/2001/XMLSchema#string

P2860

EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Surfing the p53 network

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

The tumor microenvironment controls primary effusion lymphoma growth in vivo

p21 is necessary for the p53-mediated G1 arrest in human cancer cells

p53 mutations in human cancers

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

P304

1019-1028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI30945

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Pirjo Laakkonen

P577

2007-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6443241

http://www.w3.org/2001/XMLSchema#string

P698

17364023

http://www.w3.org/2001/XMLSchema#string

P932

1810577

http://www.w3.org/2001/XMLSchema#string